Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

NH130

From Wikipedia, the free encyclopedia

Pharmaceutical compound
NH130
Clinical data
Other namesNH-130
Routes of
administration
Oral[1][2]
Drug classSerotonin 5-HT2A receptor antagonist;Antipsychotic
Pharmacokinetic data
Onset of action3.0–4.5 hours (TmaxTooltip time to peak levels
Eliminationhalf-life13.7–18.2 hours[2]

NH130 is a highlyselectiveserotonin5-HT2A receptorinverse agonist which is under development for the treatment ofParkinson's diseasepsychosis.[3][1][4][2] It is takenorally.[1][2] The drug'stime to peak levels is 3.0 to 4.5 hours and itselimination half-life is 13.7 to 18.2 hours.[2] NH130 is under development by Jiangsu Nhwa Pharmaceutical inChina.[3][1][2] As of November 2025, it is inphase 2clinical trials.[3]

See also

[edit]

References

[edit]
  1. ^abcd"NH-130 Drug Profile".Ozmosi. Retrieved18 January 2026.
  2. ^abcdefZhang K, Zhao S, Du J, Zhang L (2024)."Phase I clinical trial of NH130 and the prediction of its pharmacokinetics using physiologically based pharmacokinetic modeling".Frontiers in Pharmacology.15 1474868.doi:10.3389/fphar.2024.1474868.PMC 11424876.PMID 39329116.Following the success of pimavanserin, the search for new molecules with enhanced efficacy and an improved safety profile for treating PDP began. In Phase 1 clinical trial (CTR20230409), healthy volunteers received the compound NH130, a highly selective inverse agonist of the 5-HT2AR designed to mimic pimavanserin. The results confirmed NH130's favourable safety and tolerability. Based on these findings, further optimization of the compound and Phase 2 studies in patients with PDP are planned (K. Zhang et al., 2024).
  3. ^abc"Delving into the Latest Updates on NH-130 with Synapse".Synapse. 21 November 2025. Retrieved18 January 2026.
  4. ^Fryc M, Kluzik D, Czopek A, Jończyk J, Zagórska A (November 2025)."Serotonin 2A (5-HT2A) receptor as evolving biological target: function, structure, ligands and role in the therapy of neuropsychiatric diseases".Neuropharmacology.279 110622.doi:10.1016/j.neuropharm.2025.110622.PMID 40752586.
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Stub icon

Thisdrug article relating to thenervous system is astub. You can help Wikipedia byadding missing information.

Retrieved from "https://en.wikipedia.org/w/index.php?title=NH130&oldid=1335918697"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2026 Movatter.jp